$FROGNeutralLow

Simon Frederic sold $359K of FROG

Simon Frederic sold 4,179 shares of JFrog Ltd (FROG) at $85.81 ($0.36M total) on 2026-06-01 under a Rule 10b5-1 trading plan.

6/10
3/10
Low
Neutral
Filed June 3, 2026; transaction dated June 1, 2026.
Neutral—insider selling is a mild negative signal, but 10b5-1 reduces interpretability.

Insider selling via a pre-arranged 10b5-1 plan is typically lower-signal than discretionary sales, but it can still affect near-term sentiment.

Director Simon Frederic sold 4,179 shares of JFrog on a Rule 10b5-1 plan, disclosing $358.6K in insider selling.

Likely limited/short-lived impact; any reaction would be sentiment-driven rather than fundamental.

Background

The article is an SEC Form 4 insider transaction disclosure for JFrog (FROG).

Why it matters

The disclosure provides a datapoint on director selling, but it does not indicate a new business development, guidance change, or legal/contract event.

Market relevance

A single director sale under 10b5-1 is generally low-signal; any trading impact is likely limited to sentiment/positioning around the filing date.

Market effects

Minimal; this is company-specific insider activity with no stated operational/financial change.

None indicated.

None indicated.

Alternative perspectives

Because the sale is under a pre-arranged 10b5-1 plan, it may reflect scheduled liquidity needs rather than bearish expectations.

Traders may overreact to Form 4 sells; the key is whether there are concurrent buys/sales patterns or other non-10b5-1 disclosures, which are not provided here.

Key entities

  • JFrog Ltd

    Subject of the SEC Form 4 insider transaction disclosure.

  • Simon Frederic

    Director who sold shares under a Rule 10b5-1 plan.

Related articles

$FROGLow

JFrog (FROG) Stock Is Up, What You Need To Know

JFrog (FROG) shares rose about 3% in the afternoon after Bank of America raised its price target to $100 from $85 and kept a Buy rating, following the stock’s re-rating after JFrog’s Q1 results on May 7. The article notes other firms (Oppenheimer, Morgan Stanley, UBS) also lifted targets after Q1, with full-year guidance cited at $630 million (midpoint).